Pharmacotherapy of diabetes in cystic fibrosis patients

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 771-778

  Hardin, Dana S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

CFRD; Cystic fibrosis; Diabetes; Glucose tolerance

Indexed keywords

ACARBOSE; AVANDAI; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; NEUTRAL INSULIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CYSTIC FIBROSIS RELATED DIABETES; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIET; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERIC FEEDING; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LUNG FUNCTION; MONOTHERAPY; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; REVIEW; SYRINGE; WEIGHT REDUCTION;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CYSTIC FIBROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 77949444923     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003592151     Document Type: Review

References (36)

1. Moran A, Diem P, Klein D, et al. Pancreatic endocrine function in cystic fibrosis. J Pediatr 1991;118:715-723
2. De Luca F, Arrigo T, Nibali SC, et al. Insulin secretion, glycoslylated haemoglobin and islet cell antibodies in cystic fibrosis children and adolescents with different degrees of glucose tolerance. Horm Metab Res 1991;23:495-498
3. Lombardo F, De Luca F, Rosano M, et al. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol 2003;149:53-59
4. Moran A, Hardin DS, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis rleated diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999;45:61-73
5. Abdul-Karim FW, Dahms BB, Velasco ME, Rodman HM. Islets of Langerhans in adolescents and adults with cystic fibrosis. A quantitative study. Arch Pathol Lab Med 1986;110:602-606
6. Soejima K, Landing BH. Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies. Pediat Pathol 1986;6:25-46
7. Hardin DS, LeBlanc A, Lukenbaugh S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 1997;6:948-956
8. Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes 1994;43:1020-1026
9. Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr 2007;151:653-658
10. Costa M, Potvin S, Hammana I, et al. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros 2007;6:376-383
11. Hardin DS, LeBlanc A, Lukenbaugh S, et al. Increased rates of proteolysis associated with insulin resistance in cystic fibrosis. Pediatr 1998;101:948-956
12. Hardin DS, LeBlanc A, Para L, Seilheimer DK. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999;48:1082-1087
13. Rodman HM, Waltman SR, Krupin T, et al. Quantitative vitreous fluorophotometry in insulin-treated cystic fibrosis patients. Diabetes 1983;32:505-508
14. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056-1061
15. Andersen HU, Lanng S, Pressler T, et al. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006;29:2660-2663
16. van den Berg JM, Morton AM, Kok SW, et al. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008;7:515-519
17. Dobson L, Stride A, Ellworthy S, et al. Microalbuniuria as a screening tool in cystic fibrosis. Pediatr Pulmonol 2005;39(2):103-107
18. Allen JL. Progressive nephropathy in a patient with cystic fibrosis and diabetes mellitus. N Engl J Med 1986;315(12):764-771
19. Rolon MA, Benali K, Munck A, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001;90:860-867
20. Wilson DC, Kalnins D, Stewart C, et al. Challenges in the dietary treatment of cystic fibrosis related diabetes mellitus. Clin Nutr 2000;19:87-93
21. Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet Med 2007;24:1143-1148
22. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr Scand 1994;83:849-853
23. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162(3):891-895
24. Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009;32:1626-1631
25. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28:2141-2144
26. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017
27. Rodman HM, Doershuk CF, Roland JM. The interaction of 2 diseases: diabetes mellitus and cystic fibrosis. Medicine 1986;65:389-397
28. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988;112:373-377
29. American Diabetes Association. Standard of Medical Care-2008. Diabetes Care 2008;31(Suppl 1):12-54
30. Royal Brompton Hospital Pediatric CF Team. Clinical Guidelines: Care of Children with Cystic Fibrosis, 4th edn. Royal Brompton & Harefield NHS Trust, 2007
31. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 2009;8:174-178
32. Mohan K, Miller H, Burhan H, et al. Management of cystic fibrosis related diabetes: a survey of UK cystic fibrosis centers. Pediatr Pulmonol 2008;43:642-647
33. Onady GM, Langdon LJ. Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study. BMC Endocr Disord 2006;6:4-10
34. Milla C, Moran A. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2002;24:1706-1709
35. Elder DA, Prigeon RL, Wadwa RP, et al. Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 2006;91:185-191
36. Franzese A, Valerio G, Buono P, et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab 2008;21:109-116